Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 25Recruiting 16Active not recruiting 15Unknown 4Withdrawn 3Not yet recruiting 3Terminated 1

Sponsor Class

INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1

Conditions

Breast Neoplasms 2Pathologic Complete Response 1Neoplasm Metastasis 1

Interventions

Cisplatin 22Carboplatin 15Radiotherapy 13Paclitaxel 11Gemcitabine 10Rituximab 9Fluorouracil 9Drug Therapy 6Dexamethasone 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5Vinorelbine 4Pemetrexed 4Nivolumab 4Methotrexate 4Etoposide 4Docetaxel 4Bendamustine Hydrochloride 4spartalizumab 3pertuzumab 3pembrolizumab 3fludarabine 3Vincristine 3Trastuzumab 3Surgical Procedures, Operative 3Standard of Care 3Prednisone 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × pertuzumab × Clear all
NCT06884254 2025-10-14

EGC102

EirGenix, Inc.

Phase 3 Withdrawn
Breast

Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

NCT03811418 2019-11-26

ATTILA

iOMEDICO AG

Phase 3 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡